The FDA approved GSK's Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer who are mismatch repair deficient or microsatellite instability-high.
Jemperli is already approved, but its new formulation is indicated to be used earlier in treatment as a "frontline therapy," GSK said July 31.
In a 2022 trial of 18 patients, the drug recorded a 100 percent success rate in patients with rectal cancer. One of the researchers, Luis Diaz Jr., MD, head of the solid tumor oncology division at New York City's Memorial Sloan Kettering Cancer Center, is running similar trials with the immune checkpoint inhibitor for gastric, esophageal, prostate and pancreatic cancers.